UBS Group’s Ginkgo Bioworks DNA Stock Holding History

UBS Group’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,750	Closed	-$254K	–	9735
2022 Q4	$254K	Buy	+3,750	New	+$345K	﹤0.01%	5261

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

UBS Group's DNA Position: Q2 2026 in Review

UBS Group increased its Ginkgo Bioworks (DNA) stake by 19% in Q2 2026, buying an estimated $910K and bringing the position to 691,659 shares worth $6.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3845.

UBS Group first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

UBS Group held 691,659 shares of Ginkgo Bioworks worth $6.85M as of Q2 2026.
UBS Group bought 108,860 Ginkgo Bioworks shares in Q2 2026, an estimated $910K.
Ginkgo Bioworks made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3845 holding.
UBS Group first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.